PTN - Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data | Benzinga
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery.
The company released the mixed topline data in February 2024.
The presentation included MELODY-1 Phase 3 data results, which indicate that the Intent-to-Treat PL9643 treatment population demonstrated clinically meaningful and statistically significant results at the change from baseline to week 12 for the co-primary symptom endpoint of pain (p<0.025) and multiple exploratory secondary symptom endpoints.
The presentation also included an overview of the excellent and superior safety and tolerability profile of PL9643 compared to other approved treatments.
“Analysis of our successful ...